Bausch Health Companies (BHC) vs Kiniksa Pharmaceuticals International (KNSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Bausch Health Companies (BHC) over the past year, gaining 105.6% versus a loss of 4.7%. Over five years, KNSA leads with a +587.8% price change compared with -78.8% for BHC. Kiniksa Pharmaceuticals International is the larger company by market cap ($6.20 billion vs $2.26 billion), about 2.7 times the size.
On valuation, Bausch Health Companies trades at a lower forward P/E (1.4x vs 49.2x for Kiniksa Pharmaceuticals International). Kiniksa Pharmaceuticals International converts more of its revenue into profit, with a net margin of 8.7% versus 1.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | KNSA |
|---|---|---|
| Share price | $6.06 | $79.51 |
| Market cap | $2.26B | $6.20B |
| 1-day change | +0.25% | +0.96% |
| YTD return | -13.09% | +90.91% |
| 1-year return | -4.73% | +105.56% |
| 5-year return | -78.80% | +587.77% |
| P/E ratio (TTM) | — | 80.31 |
| Forward P/E | 1.44 | 49.15 |
| EPS (TTM) | $-2.95 | $0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.27B | $677.56M |
| Revenue growth (YoY) | +6.66% | +60.09% |
| Net income (latest FY) | $157.00M | $59.01M |
| Gross margin | — | 88.54% |
| Operating margin | 17.66% | 11.40% |
| Net margin | 1.53% | 8.71% |
| 52-week high | $8.00 | $82.94 |
| 52-week low | $4.33 | $35.20 |
| Distance from 52-week high | -24.31% | -4.14% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +23.86% | +23.26% |
| Average volume | 3.24M | 573.74K |
| Shares outstanding | 373.99M | 48.29M |
| Employees | 20,300 | 366 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Kiniksa Pharmaceuticals International is about 2.7 times larger than Bausch Health Companies by market value ($6.20B vs $2.26B).
- KNSA has outperformed BHC by 110.3 percentage points over the past year.
- Kiniksa Pharmaceuticals International is more profitable, keeping 8.7 cents of every revenue dollar as net income versus 1.5 cents for Bausch Health Companies.
- Kiniksa Pharmaceuticals International grew revenue faster in its latest fiscal year (+60.09% vs +6.66%).
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
BHC vs KNSA FAQ
Which is bigger, Bausch Health Companies or Kiniksa Pharmaceuticals International?
Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $6.20B compared with $2.26B for Bausch Health Companies (BHC).
Which stock has performed better over the past year, BHC or KNSA?
KNSA returned +105.56% over the past 12 months, compared with -4.73% for BHC (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and Kiniksa Pharmaceuticals International in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.